METROPOLIS · NSE
Metropolis Healthcare Limited
₹566
+1.31% (+₹7.3)
Prev. close
₹558.7
Volume
2,85,857
Delivery %
58.2%
As of
20 Nov 2026
Price history
Analyst sentiment
No analyst stances in this range
0 analyst stances · last 90 days · one per analyst
Try a wider range.
Explore by date range →Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on Metropolis Health for the short term, with a target of ₹2,300 and a stop loss at ₹1,900 from a CMP of ₹2,017.…” | Riyank AroraMehta Equities | Metropolis Healthcare Ltd | MISS | |
| “Bullish on Metropolis Healthcare Ltd, which is in a strong uptrend, forming higher tops and bottoms, and well-placed abo…” | Rajesh PalviyaAxis Securities | Metropolis Healthcare Ltd | HIT | |
| “Bullish on Metropolis Healthcare, recommending a buy at ₹2055.7 with a target of ₹2200 and a stop loss at ₹1983, based o…” | Sumeet BagadiaChoice Equity Broking | Metropolis Healthcare Ltd | HIT | |
| “Emkay Global Financial recommends buying Metropolis Healthcare with a target price of ₹2,050.” | Emkay Global Financial Services AnalysisEmkay Global Financial Services | Metropolis Healthcare Ltd | PENDING | |
| “Recommends buying Metropolis Healthcare with a target of ₹1,765 and a stop loss at ₹1,680.” | Jatin GediaSharekhan by BNP Paribas | Metropolis Healthcare Ltd | PENDING | |
| “Bearish on METROPOLIS, recommending a sell at ₹1,647 with a target of ₹1,515 and a stop loss at ₹1,690. The stock displa…” | Raja VenkatramanNeoTrader | Metropolis Healthcare Ltd | PENDING | |
| “Recommends selling METROPOLIS at ₹1,647 with a stop loss at ₹1,690 and a target of ₹1,515. The stock displayed a range b…” | Raja VenkatramanNeoTrader | Metropolis Healthcare Ltd | PENDING | |
| “Upgraded Metropolis Healthcare to 'Buy' with a revised DCF-based target price of ₹2,250 (from ₹2,335). Expects earnings …” | ICICI Securities AnalysisICICI Securities | Metropolis Healthcare Ltd | PENDING | |
| “Emkay Global Financial recommends buying Metropolis Healthcare with a target price of ₹2,350. The call implies a bullish…” | Emkay Global Financial Services AnalysisEmkay Global Financial Services | Metropolis Healthcare Ltd | PENDING | |
| “Bullish on Metropolis Healthcare with a target price of ₹2,515 for CY25. Metropolis Healthcare is listed as one of the t…” | BNP Paribas Research AnalysisBNP Paribas Research | Metropolis Healthcare | PENDING | |
| “Recommends buying Metropolis Healthcare Ltd. at ₹2,038, targeting ₹2,150, with a stop loss at ₹1,970.” | Vaishali ParekhPrabhudas Lilladher | Metropolis Healthcare Ltd. | PENDING | |
| “Emkay Global Financial recommends buying Metropolis Healthcare with a target price of ₹2,400. The call implies a bullish…” | Emkay Global Financial Services AnalysisEmkay Global Financial Services | Metropolis Healthcare Ltd | PENDING | |
| “Emkay Global Financial recommends buying Metropolis Healthcare with a target price of ₹2,400. The call implies a bullish…” | Emkay Global Financial Services AnalysisEmkay Global Financial Services | Metropolis Healthcare | PENDING |
Market commentary · 1 · levels, conditionals, previews, macro & hedged views — context, not graded
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on Metropolis Healthcare Ltd, which has given a consolidation breakout on the daily timeframe, supported by a po…” | Sachin Gupta5paisa | Metropolis Healthcare Ltd | — |
Fundamentals
About Metropolis Healthcare Limited
Metropolis Healthcare Limited, together with its subsidiaries, provides pathology and related healthcare services in India and internationally. The company offers routine and specialised pathology tests; advanced diagnostics, including genetic, molecular, and cytogenetic testing; preventive healthcare packages and corporate wellness screening; clinical trial research, hospital lab management, and home collection services; radiology services, including X-ray, sonography and ECG; and next-generation sequencing services. It also provides diagnostic services for oncology, chronic and infectious diseases, gastroenterology, neurology, nephrology, and women and child health, as well as various health checkup and laboratory services. The company serves a range of customers, including direct-to-consumer diagnostics through patient service centers, mobile app, website, and home collection; partnerships with standalone labs, hospital chains, and diagnostic networks; and institutional clients, such as corporates, government bodies, and hospital lab management services. Metropolis Healthcare Limited was founded in 1980 and is headquartered in Mumbai, India.
Details
Sector
Healthcare
Industry
Diagnostics & Research
CEO
Ms. Ameera Sushil Shah
Headquarters
Mumbai
Employees
4,484
Website
metropolisindia.comExchange
View on NSE ↗Key stats
Market cap
₹11,997.25 Cr
P/E ratio (TTM)
53.6
Dividend yield
0.35%
EPS (TTM)
₹10.78
Beta (1Y · daily vs NIFTY 50)
0.46
Beta (5Y · monthly vs NIFTY 50)
0.91
Shares float
10.61 Cr
EPS · quarter ended Jun 2026
₹2.73
Upcoming earnings
03 Feb 2027
Financial Performance
01 · Financials
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹997.99 Cr | ₹1,228.34 Cr | ₹1,148.21 Cr | ₹1,207.71 Cr | ₹1,331.20 Cr | ₹1,645.85 Cr | |
EBITDA | ₹298.05 Cr | ₹376.32 Cr | ₹303.52 Cr | ₹291.69 Cr | ₹318.11 Cr | ₹417.44 Cr |
| ₹183.10 Cr | ₹214.18 Cr | ₹142.88 Cr | ₹127.82 Cr | ₹144.97 Cr | ₹190.02 Cr | |
Diluted EPS | ₹8.95 | ₹10.42 | ₹6.95 | ₹6.22 | ₹7.04 | ₹9.19 |
EBITDA for Mar 2022 could not be checked against the company's own annual report: this page shows ₹376.32 Cr while the annual report gives ₹360.42 Cr (4.2% apart). That disagreement leaves the whole cross-check inconclusive, so EBITDA for Mar 2020 (the annual report alone gives ₹241.39 Cr) is left blank here too, rather than shown from only one of the two sources.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹1,000.00 Cr | ₹1,521.00 Cr | ₹1,495.00 Cr | ₹1,547.00 Cr | ₹1,859.00 Cr | ₹2,131.00 Cr | |
| ₹112.27 Cr | ₹378.56 Cr | ₹266.38 Cr | ₹197.06 Cr | ₹204.13 Cr | ₹231.91 Cr | |
Stockholders' equity | ₹706.00 Cr | ₹886.00 Cr | ₹988.00 Cr | ₹1,096.00 Cr | ₹1,331.00 Cr | ₹1,513.00 Cr |
CWIP, Others, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹249.00 Cr | ₹253.00 Cr | ₹247.00 Cr | ₹264.00 Cr | ₹263.00 Cr | ₹351.00 Cr | |
Investing cash flow | ₹61.70 Cr | ₹-735.05 Cr | ₹46.79 Cr | ₹-89.41 Cr | ₹-201.06 Cr | ₹-223.13 Cr |
| ₹-33.00 Cr | ₹163.00 Cr | ₹-292.00 Cr | ₹-181.00 Cr | ₹-87.00 Cr | ₹-115.00 Cr | |
Capital expenditure | ₹-28.27 Cr | ₹-30.66 Cr | ₹-52.63 Cr | ₹-63.76 Cr | ₹-68.61 Cr | ₹-51.18 Cr |
End cash position | ₹386.59 Cr | ₹65.98 Cr | ₹68.83 Cr | ₹62.62 Cr | ₹39.48 Cr | ₹54.78 Cr |
Debt issued, Debt repaid have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21 | Dec 21 | Mar 22–Jun 22(2Q) | Sep 22–Dec 22(2Q) | Mar 23–Jun 23(2Q) | Sep 23–Dec 23(2Q) | Mar 24 | Jun 24 | Sep 24 | Dec 24 | Mar 25 | Jun 25–Sep 25(2Q) | Dec 25 | Mar 26–Mar 26(2Q) | Jun 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 50.33% | 49.50% | 49.79% | 49.76% | 49.75% | 49.74% | 49.67% | 49.62% | 49.43% | 49.40% | 48.90% | 48.89% | 48.88% | 48.87% | 48.86% |
| Public | 49.67% | 50.50% | 50.21% | 50.24% | 50.25% | 50.26% | 50.33% | 50.38% | 50.57% | 50.60% | 51.10% | 51.11% | 51.12% | 51.13% | 51.14% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.25 L Cr | ₹1,769.9 | 38.8 | 5.09 | 13.7% | 0.06 | +11.9% | +3.7% |
| Divi's Laboratories Limited | ₹2.66 L Cr | ₹10,037.5 | 90.8 | 15.85 | 15.3% | 0.00 | +12.3% | +47.5% |
| Torrent Pharmaceuticals Limited | ₹1.79 L Cr | ₹4,738.5 | 79.4 | 21.31 | 25.8% | 1.79 | +21.5% | +32.5% |
| Laurus Labs Limited | ₹1.27 L Cr | ₹2,348 | 94.8 | 23.94 | 16.8% | 0.48 | +22.0% | +146.2% |
| Apollo Hospitals Enterprise Limited | ₹1.23 L Cr | ₹8,599.5 | 58.8 | 12.95 | 20.5% | 0.90 | +15.7% | +10.1% |
| Zydus Lifesciences Limited | ₹1.19 L Cr | ₹1,188.1 | 26.7 | 4.40 | 18.6% | 0.46 | +18.4% | +22.3% |
| Lenskart Solutions Limited | ₹1.16 L Cr | ₹689.7 | 181.4 | 13.30 | 5.6% | 0.35 | +35.4% | — |
| Dr. Reddy's Laboratories Limited | ₹1.14 L Cr | ₹1,374 | 40.6 | 3.02 | 11.4% | 0.21 | +3.2% | +14.5% |
| Cipla Limited | ₹1.13 L Cr | ₹1,402 | 38.9 | 3.27 | 11.3% | 0.02 | +2.1% | -6.7% |
| Mankind Pharma Limited | ₹1.03 L Cr | ₹2,475 | 45.9 | 6.31 | 11.7% | 0.39 | +17.0% | +3.1% |
| Aurobindo Pharma Limited | ₹98,101.93 Cr | ₹1,705 | 26.6 | 2.59 | 9.2% | 0.21 | +6.4% | +48.4% |
| Metropolis Healthcare Limited | ₹11,849.27 Cr | ₹581.25 | 53.0 | 7.83 | 12.6% | 0.15 | +23.6% | -71.4% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
IPO documents
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
3 indices
Metropolis Healthcare Q2: Net profit jumps 43% on higher test volumes, specialty and B2C growth
CNBC TV18 · 19 days ago